GIP/GLP-1 & amylin agonists × body weight & composition

TrialThe New England journal of medicine2025

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

W Timothy Garvey et al.PubMed ↗Publisher ↗

  • Cagrilintide-semaglutidelooks good hereLower percent change in body weight from baseline to week 68.Randomised, large.

What the trial testedrandomised · 3,417 people · 2025

Randomised vs placebo

Lowered percent change in body weight from baseline to week 68

−17.3percentage points−18.1 to −16.6

cagrilintide-semaglutide vs placebo

As reported

difference −17.3 percentage points, 95% CI −18.1 to −16.6 · the paper's word: mean percent change in body weight from baseline to week 68

Who was studied, and how

3,417people with obesity, in this paper

The trial randomly assignedassigned by chance

cagrilintide-semaglutide
placebo

Lowered percent change in body weight from baseline to week 68−17.3

randomised

the abstract, start to end

with placebo (estimated difference, -17.3 percentage points; 95%

← favours treatmentfavours comparator →
could be chance
Mean percent change in body weight from baseline to week 68cagrilintide-semaglutide vs placebo
−17.3−18.1 to −16.6
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsBody weight & composition

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.001.00 without it

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

79 papers cite itlatest 60 shown

2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 40544433